8-K
filed April 9, 2024, 7:59 PM ET
ticker JAGX
CIK 0001585608
other material
confidence high
sentiment neutral
materiality 0.70
Jaguar Health shareholders approve reverse split authorization; Nasdaq extends compliance deadline to Aug 13, 2024
Jaguar Health, Inc.
- Stockholders approved all four proposals at April 9 special meeting, including reverse split authorization up to 1-for-150.
- Company does not intend to implement reverse split at this time but seeks flexibility to maintain Nasdaq listing.
- Nasdaq granted extension until August 13, 2024 to regain $1 minimum bid price compliance.
- Phase 3 OnTarget trial top-line results for crofelemer in cancer therapy-related diarrhea are forthcoming.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Jaguar Health, Inc. shareholders approved Approve amendment to Third Amended and Restated Certificate of Incorporation to effect reverse stock split at ratio of not less than 1-for-2 and not greater than 1-for-150 at the 2024-04-09 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2024-04-09
Exact text from the filing
1. Proposal to approve an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company’s issued and outstanding voting common stock, par value $0.0001 per share, at a ratio of not less than 1-for-2 and not greater than 1-for-150, with the exact ratio, if approved and effected at all, to be set within that range at the discretion of the Company’s board of directors and publicly announced by the Company on or before January 22, 2025 without further approval or authorization of the Company’s stockholders, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 73,520,240 19,147,290 285,853 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Jaguar Health, Inc. shareholders approved Approve issuance of common stock upon exchange of Series J Preferred Stock to certain accredited investors at the 2024-04-09 meeting.
- Outcome
- passed
- Meeting
- 2024-04-09
Exact text from the filing
2. Proposal to approve, pursuant to Nasdaq Marketplace Rule 5635(d), the issuance of Company’s common stock upon exchange of shares of Series J Preferred Stock issued to certain accredited investors, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 34,430,429 11,120,770 1,024,155 25,722,981
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Jaguar Health, Inc. shareholders approved Approve issuance of common stock pursuant to PIPE Warrant Exchange Agreements at the 2024-04-09 meeting.
- Outcome
- passed
- Meeting
- 2024-04-09
Exact text from the filing
3. Proposal to approve, pursuant to Nasdaq Marketplace Rule 5635(d), the issuance of 18,837,500 shares of Common Stock to certain accredited investors pursuant to the exchange agreements, dated February 27, 2024, between us and such investors (the “PIPE Warrant Exchange Agreements”), in exchange for certain warrants to acquire shares of Common Stock previously issued to such investors, was approved by the stockholders by the following vote: For Against Abstained Broker Non- Votes 55,863,424 10,656,130 710,848 25,722,981
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Jaguar Health, Inc. shareholders approved Approve adjournment of Special Meeting to solicit additional proxies if necessary at the 2024-04-09 meeting.
- Outcome
- passed
- Meeting
- 2024-04-09
Exact text from the filing
4. Proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1, 2, and 3 was approved by the stockholders by the following vote : For Against Abstained Broker Non- Votes 75,565,231 15,556,724 1,831,428 0
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.